Key result
Intensive antihypertensive treatment fails to reduce major cardiovascular events versus standard care in women <65.
Why the study?
Predictability of clinical outcomes in hypertension in underrepresented populations is key to rational treatment, prompting evaluation of how baseline characteristics impact outcomes and serious adverse events in hypertensive women aged <65 years.
Does intensive antihypertensive treatment improve clinical outcomes compared to standard treatment in hypertensive women aged <65 years?
RCT (n=1,247)
randomized
Yes
Does intensive antihypertensive treatment improve clinical outcomes compared to standard treatment in hypertensive women aged <65 years?
In middle-aged hypertensive women, intensive blood pressure lowering did not significantly reduce primary cardiovascular outcomes compared to standard therapy, but baseline factors like smoking, aspirin use, CKD, and black race were important predictors of adverse events.
Answers are grounded in this paper and cite their sources.
Baseline characteristics may predict outcomes and SAEs in younger hypertensive women; leaves open optimal BP targets in this subgroup.
Background/aim: The predictability of clinical outcomes in hypertension in specific patient groups, especially underrepresented populations is the key to rational treatment. This study aimed to investigate the impact of baseline characteristics of <65-year-old hypertensive women with an increased risk of cardiovascular events, managed with standard- or intensive-approach, on their clinical outcomes and serious adverse events (SAEs). Materials and methods: Baseline characteristics of <65-year-old hypertensive women (n = 1247) in SPRINT, a multicenter randomized trial to compare standard and intensive antihypertensive treatment, were analyzed with Cox-regression method to determine potential predictors of the clinical outcomes and SAEs. The primary outcome was the composite of myocardial infarction (MI), non-MI acute coronary syndrome, stroke, heart failure, or cardiovascular death. Results: The primary outcome occurred in 3.1% and SAEs in 27.6% of the population. The treatment groups were similar in terms of the primary outcome, SAEs, or their individual components. The primary outcome occurred significantly more in current smokers vs. nonsmokers (HR: 2.85, 95% CI: 1.34–6.09). The subjects who were on aspirin in the intensive-group were significantly more likely to develop the primary outcome (HR: 3.17, 95% CI: 1.23-8.19) and MI (HR: 10.15, 95% CI: 1.19-86.88) compared with those not using aspirin. The risk of overall SAEs was significantly higher in blacks vs. nonblacks (HR: 1.27, 95% CI: 1.01-1.58), in current-smokers vs. nonsmokers (HR: 1.59, 95% CI: 1.23-2.05), and those with vs. without chronic kidney disease (CKD), (HR: 1.38, 95% CI: 1.08-1.77). The likelihood of SAEs significantly increased with age (HR: 1.04, 95% CI: 1.01-1.07). Conclusion: Smoking, aspirin, CKD, black race, and age seemed as important baseline characteristics in follow-up of <65-year-old hypertensive women, also depending on therapeutic strategy. Clinicians are expected to consider these critical parameters for effective antihypertensive management that promotes better outcomes in this middle-aged female population.
No takes yet. Share an insight, caveat, or question.
Aydın et al. (2020) conducted an RCT in Hypertension (n=1,247). Intensive antihypertensive treatment vs. Standard antihypertensive treatment was evaluated on Composite of myocardial infarction (MI), non-MI acute coronary syndrome, stroke, heart failure, or cardiovascular death. Intensive antihypertensive treatment yielded similar primary cardiovascular outcomes to standard treatment in women <65 years, while smoking and aspirin use increased risk.
Synapse has enriched 10 related papers. Consider them for comparative context: